The Irish Working Group against Vaccines recommends temporary cessation following reports of blood clots among those who received COVID stroke.
The Irish Vaccine Working Group has recommended temporarily suspending the launch of the AstraZeneca coronavirus test, following reports of blood clots in adults who received the shot.
“The National Vaccination Advisory Committee (NIAC) has recommended that the administration of the COVID-19 AstraZeneca vaccine be temporarily postponed from this morning,” Irish Deputy Director Ronan Glynn said in a statement on Sunday. .
He said the recommendation was made “by the precautionary principle” after “a report from the Norwegian Medicines Agency of four new reports of serious blood clotting events in adults after vaccination.”
The NIAC will meet Sunday morning and issue a new statement on the matter.
Jonah Hull, of Al Jazeera, a London informant, said the measure by the Irish working group was worrisome for the drug maker.
“The company has made very rapid progress on this and has strongly defended its vaccine, noting that safety data compiled over the past two months show no evidence of an increased risk of pulmonary embolism or thrombosis.” , said Hull.
The recommendation comes at a time when the Irish authorities have pressured the pharmaceutical company to speed up supplies in the country.
About 570,000 doses of coronavirus vaccine have been administered so far in Ireland, according to government data last updated on Wednesday.
A total of 109,000 of these doses have been manufactured by Anglo-Swedish pharmaceutical giant AstraZeneca, which developed its vaccine with Oxford University.
Meanwhile, Norway announced on Thursday that it was also stopping the use of the AstraZeneca vaccine.
“This is a precautionary decision,” Geir Bukholm, director of infection prevention and control at the Norwegian Institute of Public Health (FHI), told a news conference.
FHI did not say how long the suspension would last.
“We are waiting for information to see if there is a link between vaccination and this case with a blood clot,” Bukholm said.
Also Thursday, Italy said it would suspend the use of a different AstraZeneca batch than was used in Austria.
Austria has stopped using a batch of AstraZeneca shots while investigating a death from clotting disorders and a disease from a pulmonary embolism.
Denmark will not use AstraZeneca’s COVID-19 vaccine for two weeks after reporting that some recipients had developed severe blood clots and that in one case they may have died as a result, authorities said on Thursday. They did not say how many reports of blood clots there had been.
Meanwhile, AstraZeneca told Reuters news agency in a written statement that the safety of its vaccine had been extensively studied in human trials and that peer-reviewed data confirmed that the vaccine was generally well tolerated.